MedPath

PRETREATMENT WITH HIGH DOSE CLOPIDOGREL FOR REDUCTION OF THROMBOTIC EVENTS AFTER ELECTIVE CORONARY TERRITORY STENTING WITH DRUG ELUTING STENTS: ThePROTECTED Study - The PROTECTED Study

Conditions
PERCUTANEOUS CORONARY INTERVENTION( USING DRUG ELUTING STENTS)
Registration Number
EUCTR2004-000517-19-GB
Lead Sponsor
Blackpool Fylde & Wyre Healthcare NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
100
Inclusion Criteria

Consecutive patients suitable for elective coronary stenting using Drug eluting stents will be eligible and recruited for the study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion criteria will be history of bleeding diathesis, acute myocardial infarction or acute coronary syndrome/troponin elevation within 14 days, stroke within 3 months, drug or alcohol abuse, pro-thrombin time >1.5 times control, platelet count <100,000/cu.mm, hematocrit <25%, serum creatinine > 4.0mg/dl, or previous use of theinopyridines or GP IIb/IIIa inhibitors

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath